R. Ibrahim

发表

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma.

Axel Hoos, Alessandro Testori, Axel Hauschild, 2011, The New England journal of medicine.

Idiopathic Thrombocytopenia with Iron Deficiency Anemia

Tyler T. Cooper, R. Ibrahim, Jaffar Ahmad Alhilli, 2013, Clinical medicine insights. Blood disorders.

Tremelimumab as second- or third-line treatment of unresectable malignant mesothelioma (MM): Results from the global, double-blind, placebo-controlled DETERMINE study.

K. Nackaerts, J. Aerts, F. Grosso, 2016 .

Preliminary data from a multi-arm expansion study of MEDI4736, an anti-PD-L1 antibody.

N. Segal, M. Maio, S. Antonia, 2014 .

A phase 1 study of MEDI4736, an anti–PD-L1 antibody, in patients with advanced solid tumors.

N. Segal, S. Antonia, J. Lutzky, 2014 .

Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group

M. Suarez‐Almazor, M. Lacouture, I. Puzanov, 2017, Journal of Immunotherapy for Cancer.

A Novel Anti-CD22 Immunotoxin, Moxetumomab Pasudotox: Phase I Study in Pediatric Acute Lymphoblastic Leukemia (ALL)

C. Pui, I. Pastan, L. Silverman, 2011 .

Clinical activity and biomarkers of MEDI4736, an anti-PD-L1 antibody, in patients with NSCLC.

N. Rizvi, S. Antonia, J. Brahmer, 2014 .

A phase 2 randomized, double-blind, placebo-controlled study of tremelimumab for second and third line treatment in patients with unresectable pleural or peritoneal mesothelioma

L. Krug, H. Kindler, R. Narwal, 2013, Journal of Immunotherapy for Cancer.

Abstract B80: A Phase II randomized, double-blind, placebo-controlled study of tremelimumab for second- and third-line treatment in patients with unresectable pleural or peritoneal mesothelioma.

L. Krug, M. Maio, H. Kindler, 2013 .

Continuous systemic corticosteroids do not affect the ongoing regression of metastatic melanoma for more than two years following ipilimumab therapy

M. Binder, H. Pehamberger, K. Harmankaya, 2011, Medical oncology.

Ipilimumab efficacy and safety in patients with advanced melanoma: a retrospective analysis of HLA subtype from four trials.

D. Schadendorf, J. Wolchok, M. Maio, 2010, Cancer immunity.

Neutropenia in a patient treated with ipilimumab (anti-CTLA-4 antibody).

E. Waller, M. Arellano, D. Jaye, 2009, Journal of immunotherapy.

Accelerating the development of innovative cellular therapy products for the treatment of cancer.

Christopher G. Ramsborg, J. Bluestone, L. Butterfield, 2020, Cytotherapy.

Resolution of severe ipilimumab-induced hepatitis after antithymocyte globulin therapy.

R. Kefford, B. Nankivell, C. Liddle, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Evaluation of the effect of systemic corticosteroids for the treatment of immune-related adverse events (irAEs) on the development or maintenance of ipilimumab clinical activity.

B. Neyns, M. Maio, S. O’Day, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Triad of Iron Deficiency Anemia, Severe Thrombocytopenia and Menorrhagia—A Case Report and Literature Review

Areej Khan, S. Raza, R. Ibrahim, 2012, Clinical medicine insights. Case reports.

Addressing current challenges and future directions in immuno-oncology: expert perspectives from the 2017 NIBIT Foundation Think Tank, Siena, Italy

G. Coukos, J. Wolchok, Z. Trajanoski, 2018, Cancer Immunology, Immunotherapy.

Efficacy and safety of ipilimumab induction and maintenance dosing in patients with advanced melanoma who progressed on one or more prior therapies

H. Pehamberger, V. Chiarion-Sileni, M. Maio, 2008 .

Ipilimumab safety profile: Summary of findings from completed trials in advanced melanoma.

A. Hoos, Tai-Tsang Chen, D. Berman, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Development of ipilimumab: contribution to a new paradigm for cancer immunotherapy.

A. Korman, A. Hoos, D. Berman, 2010, Seminars in oncology.

Positive Response of Vitamin D Therapy in Conjunction with Conventional Treatments of Reactive Airways Dysfunction Syndrome (RADS)

Yitzchak Weinberger, Tyler T. Cooper, R. Ibrahim, 2013 .

Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial

Christopher R. Cabanski, Vanessa M. Hubbard-Lucey, E. Wherry, 2022, Nature Medicine.

Novel efficacy criteria for antitumor activity to immunotherapy using the example of ipilimumab, an anti-CTLA-4 monoclonal antibody

H. Pehamberger, J. Wolchok, F. Hodi, 2008 .

Antitumor response and new lesions in advanced melanoma patients on ipilimumab treatment

J. Wolchok, P. Queirolo, K. Harmankaya, 2008 .

Expression of FasL in squamous cell carcinomas of the cervix and cervical intraepithelial neoplasia and its role in tumor escape mechanism

Y. Ward, S. Khleif, A. Parr, 2006, Cancer.

CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b study.

Christopher R. Cabanski, Lacey J. Kitch, Vanessa M. Hubbard-Lucey, 2021, The Lancet. Oncology.

Pharmacokinetics of MEDI4736, a fully human anti-PDL1 monoclonal antibody, in patients with advanced solid tumors.

L. Roskos, R. Narwal, P. Robbins, 2014 .

Effectiveness of treatment guidance on diarrhea and colitis across ipilimumab studies.

J. Wolchok, P. Lorigan, S. O’Day, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Paget-Schroetter syndrome in the absence of common predisposing factors: a case report

R. Pekmezaris, A. Kozikowski, Myia S. Williams, 2017, Thrombosis Journal.

Improved Endpoints for Cancer Immunotherapy Trials

Sylvia Janetzki, Axel Hoos, J. Wolchok, 2010, Journal of the National Cancer Institute.

Re-induction with ipilimumab, gp100 peptide vaccine, or a combination of both from a phase III, randomized, double-blind, multicenter study of previously treated patients with unresectable stage III or IV melanoma.

J. Wolchok, F. Hodi, J. Haanen, 2010 .

Celiac Artery Compression Syndrome

R. Ibrahim, J. Hermann, A. Rabah, 2020 .

Pulmonary embolism secondary to uterine fibroid: A case report of a rare presentation

R. Pekmezaris, A. Kozikowski, Myia S. Williams, 2018 .

Immunotherapy for brain metastases and primary brain tumors.

M. Maio, A. Anichini, M. Weller, 2022, European journal of cancer.

Future cancer research priorities in the USA: a Lancet Oncology Commission.

Quynh-Thu Le, Martin G Pomper, Levi Garraway, 2017, The Lancet. Oncology.

A vision of immuno-oncology: the Siena think tank of the Italian network for tumor biotherapy (NIBIT) foundation

B. Fox, M. Maio, A. Covre, 2021, Journal of experimental & clinical cancer research : CR.

Development of a PD-L1 companion diagnostic assay for treatment with MEDI4736 in NSCLC and SCCHN patients.

K. Steele, M. Rebelatto, Jill Walker, 2015 .

PD-L1 blockade for cancer treatment: MEDI4736.

R. Stewart, R. Ibrahim, A. Shalabi, 2015, Seminars in oncology.

A pilot clinical trial testing mutant von Hippel-Lindau peptide as a novel immune therapy in metastatic Renal Cell Carcinoma

S. Steinberg, J. Berzofsky, W. Linehan, 2010, Journal of Translational Medicine.

Do Sociodemographic Factors Influence Outcome in Prostate Cancer Patients Treated With External Beam Radiation Therapy?

I. Chetty, B. Movsas, F. Siddiqui, 2016, American journal of clinical oncology.

Ipilimumab alone or in combination with nivolumab in patients with advanced melanoma who have progressed or relapsed on PD-1 blockade: clinical outcomes and translational biomarker analyses

Christopher R. Cabanski, Daniel K. Wells, P. Gherardini, 2022, Journal for ImmunoTherapy of Cancer.

CTLA4 blockade in mesothelioma: finally a competing strategy over cytotoxic/target therapy?

G. Ceresoli, M. Maio, L. Calabrò, 2014, Cancer Immunology, Immunotherapy.

Methods of fixation used in management of femoral neck fractures in adults: a systematic review

A. Gouda, R. Ibrahim, A. F. Abdel Rahman, 2018, Current Orthopaedic Practice.

Association between immune-related adverse events (irAEs) and disease control or overall survival in patients (pts) with advanced melanoma treated with 10 mg/kg ipilimumab in three phase II clinical trials.

H. Pehamberger, G. Linette, J. Wolchok, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Neoadjuvant immunotherapy is reshaping cancer management across multiple tumour types: The future is now!

B. Fox, A. Eggermont, C. Blank, 2021, European journal of cancer.

Direct economic burden of high-risk and metastatic melanoma in the elderly

J. Wolchok, D. Mitra, K. Davis, 2009 .

New Cancer Immunotherapy Agents in Development: a report from an associated program of the 31stAnnual Meeting of the Society for Immunotherapy of Cancer, 2016

G. Freeman, C. Drake, M. Cornfeld, 2017, Journal of Immunotherapy for Cancer.

EFFICACY AND SAFETY OF IPILIMUMAB IN PATIENTS WITH ADVANCED MELANOMA WHO HAD PROGRESSED ON ONE OR MORE PRIOR THERAPIES: RESULTS FROM A SINGLE-ARM, MULTICENTER STUDY

H. Pehamberger, J. Wolchok, M. Maio, 2008 .

Identification of H-2Db-Specific CD8+ T-Cell Epitopes From Mouse VEGFR2 That Can Inhibit Angiogenesis and Tumor Growth

J. Berzofsky, S. Khleif, J. Qian, 2006, Journal of immunotherapy.

Combined prophylactic and therapeutic cancer vaccine: Enhancing CTL responses to HPV16 E2 using a chimeric VLP in HLA‐A2 mice

J. Berzofsky, J. Schiller, S. Khleif, 2006, International journal of cancer.

Unusual Presentation of May-Thurner Syndrome:A Case Report and Review of Literature

R. Ibrahim, J. Hermann, M. M. Salama, 2020 .

The Italian Network for Tumor Bio-Immunotherapy (NIBIT) Foundation: ongoing and prospective activities in immuno-oncology

M. Maio, P. Natali, A. Covre, 2018, Cancer Immunology, Immunotherapy.

9312 Antitumor responses to ipilimumab in advanced melanoma are not affected by systemic corticosteroids used to manage immune-related adverse events (irAEs)

J. Wolchok, B. Neyns, J. Grob, 2009 .

Vitamin D Deficiency in the Setting of Multiple Sclerosis-A Case Report and Literature

R. Ibrahim, I. Dashkova, J. Hermann, 2020 .

Safety and disease response to MEDI-551, an anti-CD19 antibody, in chronic lymphocytic leukemia patients previously treated with rituximab

B. Cheson, T. Kipps, A. Cuneo, 2013, Journal of Immunotherapy for Cancer.

Immune Checkpoint Inhibitors for Cancer Therapy in the COVID-19 Era

J. Wolchok, J. Larkin, C. Robert, 2020, Clinical Cancer Research.

A Novel Anti-CD22 Immunotoxin, Moxetumomab Pasudotox (HA22, CAT-8015): Activity in Pediatric Patients with Relapsed Acute Lymphoblastic Leukemia (ALL) After Allogeneic Hematopoietic Stem Cell Transplantation (SCT)

I. Pastan, L. Silverman, J. Whitlock, 2012 .

Resolution of Hairy Cell Leukemia Minimal Residual Disease by Both BRAF and Clone-Specific Real-Time Quantitative PCR (RQ-PCR) After Treatment with Moxetumomab Pasudotox.

W. Wilson, I. Pastan, M. Raffeld, 2012 .

Efficacy of ipilimumab 10 mg/kg in advanced melanoma patients (pts) with good and poor prognostic factors.

G. Linette, J. Wolchok, V. Chiarion-Sileni, 2009, Journal of Clinical Oncology.

Effect of ipilimumab at 10 mg/kg on disease control in patients (pts) with M1c-stage melanoma in relation to baseline lactate dehydrogenase (LDH) levels.

D. Schadendorf, M. Smylie, B. Neyns, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Rare Presentation of Cancer Bladder

R. Ibrahim, J. Shah, M. William, 2020 .

Abstract CT230: Pediatric phase 1 trial of moxetumomab pasudotox: Activity in chemotherapy refractory acute lymphoblastic leukemia (ALL)

I. Pastan, L. Silverman, J. Whitlock, 2014 .

767O TREATMENT OF PATIENTS WITH ADVANCED REFRACTORY OR RELAPSED MELANOMA IN A PHASE II STUDY OF TREMELIMUMAB (CP-675,206), AN ANTI-CTLA4 MONOCLONAL ANTIBODY

A. Hauschild, D. Schadendorf, H. Pehamberger, 2008 .

Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study.

H. Pehamberger, J. Wolchok, P. Queirolo, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

Mutant P53 vaccination of patients with advanced cancers generates specific immunological responses.

J. Berzofsky, S. Khleif, R. Ibrahim, 2004, Journal of Clinical Oncology.

Future cancer research priorities in the USA: a Lancet Oncology Commission.

Mark E. Davis, E. Mardis, A. Butte, 2017, The Lancet Oncology.

The Italian Network for Tumor Bio-Immunotherapy (NIBIT) Foundation: ongoing and prospective activities in immuno-oncology

M. Maio, P. Natali, A. Covre, 2018, Cancer Immunology, Immunotherapy.

Safety Profile and Clinical Response To MEDI-551, a Humanized Monoclonal Anti-CD19, In a Phase 1/2 Study In Adults With Relapsed Or Refractory Advanced B-Cell Malignancies

B. Cheson, T. Kipps, M. Federico, 2013 .

Neutropenia in a patient treated with ipilimumab (anti-CTLA-4 antibody).

E. Waller, M. Arellano, D. Jaye, 2009, Journal of immunotherapy.

Randomized, double-blind, placebo-controlled study of tremelimumab for second- and third-line treatment of unresectable pleural or peritoneal mesothelioma.

A. Tsao, M. Maio, P. Vasey, 2014 .